Levofloxacin/prednisolone
Alternative Names: DE 094; Levofloxacin/prednisolone ALatest Information Update: 20 Feb 2013
Price :
$50 *
At a glance
- Originator Daiichi Sankyo Company
- Developer Daiichi Sankyo Company; Santen Pharmaceutical
- Class Anti-inflammatories; Antiallergics; Antibacterials; Eye disorder therapies; Fluoroquinolones; Glucocorticoids; Small molecules
- Mechanism of Action Glucocorticoid receptor agonists; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Infectious keratitis
Most Recent Events
- 31 Jul 2010 Discontinued - Phase-II for Infectious keratitis in USA (Topical)
- 20 Oct 2009 Levofloxacin/prednisolone is still in phase II trials for Infectious Keratitis in the US
- 30 Jan 2008 Levofloxacin/prednisolone is still in phase II trials for Infectious keratitis in USA